RPE Cell Purity via Segmented Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protocols for deriving retinal pigment epithelium (RPE) cells from pluripotent stem cells yield mixed populations, making it challenging to obtain pure populations necessary for therapeutic and research applications, and there is a limited supply of adult and fetal RPE cells due to ethical and practical issues.
Innovation Solution
A method involving the ex-vivo differentiation of human embryonic stem cells using specific culture conditions and media compositions, including the use of nicotinamide and activin A, to generate RPE cells that co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), with enhanced trans-epithelial electrical resistance and polarized secretion of specific factors, resulting in a population of at least 95% pure RPE cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current protocols are used to derive RPE cells from pluripotent stem cells, then RPE cells can be generated, but the cell population is mixed and not pure enough for therapeutic applications
Solution Approach 1:
The differentiation protocol is divided into distinct temporal stages: initial differentiation stage (days 0-7) where cells are exposed to activin A and FGF2 to form RPE progenitors, and secondary differentiation stage (days 8-21) where cells are exposed to retinoic acid and FGF2 to generate mature pigmented RPE cells. This segmentation allows selective purification at each stage, achieving >95% purity by removing non-RPE cell types at the progenitor stage before final differentiation.
Solution Approach 2:
The protocol performs preliminary differentiation into RPE progenitors before final maturation. By first generating a population enriched for RPE lineage cells (with >80% purity) at the progenitor stage, and then completing differentiation under controlled conditions, the method achieves high final purity that would be difficult to attain by direct differentiation alone.
2Quantity of substance
If adult and fetal RPE cells are used as donor sources, then sufficient tissue supply can be obtained, but ethical concerns and practical limitations restrict widespread use
Solution Approach 1:
The patent creates functional copies of adult RPE cells by differentiating pluripotent stem cells into mature pigmented RPE cells that replicate the morphology, marker expression (PMEL17, CRALBP, RPE65), and functional properties of adult RPE. These stem cell-derived copies provide an unlimited supply without the ethical constraints of using aborted fetal tissue or requiring adult donor coordination.
Solution Approach 2:
The protocol manipulates culture conditions (temperature, oxygen levels, growth factors) to control the differentiation trajectory. By adjusting these parameters, the method generates RPE cells with adult-like characteristics from pluripotent stem cells, achieving both unlimited supply and functional equivalence to adult donor cells.
3Manufacturing precision
If mixed populations of pigmented and non-pigmented cells are obtained, then differentiation can occur, but pure pigmented RPE cell populations are required for therapeutic applications
Solution Approach 1:
The protocol segments the differentiation process into two phases where purification occurs at the progenitor stage before final maturation. This timing allows removal of non-RPE cells when they are most distinguishable, achieving >95% purity by day 7 before the final pigmentation stage, thereby reducing the overall time required compared to attempting purification after complete differentiation.
Solution Approach 2:
The protocol incorporates quality control checks at the progenitor stage to assess RPE lineage enrichment before committing to final differentiation. This feedback mechanism allows optimization of the differentiation conditions based on actual cell population composition, ensuring efficient purification and reducing unnecessary time expenditure.
Data Source
AI summary
A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.